The proportion of patients with drug-susceptible tuberculosis with peak ALT or AST of at least 5 × ULN was higher for the BloadPaZ (six [10%] of 59 patients) and B200PaZ (four [7%] of 60 patients) groups than for patients receiving HRZE (three [5%] of 61 patients; table 6). This evidence concerns the gene GPT and tuberculosis.